Drug intelligence / Profile preview

BMK-MMAE

Development stage: Preclinical
Lead developer: Hengrui Pharmaceutical
Modality: Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics
Administration: Intravenous

Overview

BMK-MMAE is a benchmark antibody-drug conjugate (ADC) synthesized by Jiangsu Hengrui Pharmaceuticals based on the published structure of ladiratuzumab vedotin. It consists of a monoclonal antibody targeting LIV-1 (SLC39A6) conjugated to the microtubule-disrupting cytotoxic agent monomethyl auristatin E (MMAE). BMK-MMAE is utilized in preclinical studies as a reference standard to evaluate the efficacy and safety of novel LIV-1-targeted ADCs, such as SDP03923-000-9106.

Targets

TUBB (Tubulin (alpha and beta subunits))SLC39A6 (Solute carrier family 39 member 6)

Beyond the preview

Go deeper on BMK-MMAE.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on BMK-MMAE.

Explore the full profile